Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,530 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration.
Feng D, Jiang H, Chen G, Guan W, Yi L, Zhu Y, Li Y, Huang G, He B, Tang J, Tang Y, Zeng J, Zhou W, Shi J, Xie Z, Liu M, Xie X, Lin X, Zhou C. Feng D, et al. Among authors: xie x, xie z. Front Immunol. 2024 Dec 9;15:1485358. doi: 10.3389/fimmu.2024.1485358. eCollection 2024. Front Immunol. 2024. PMID: 39717770 Free PMC article.
Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II Study.
Jiang H, Sun N, Li R, Guan W, Zhu Y, Xie Z, Xie X, Liu M, Lin X, Zhou C. Jiang H, et al. Among authors: xie x, xie z. Clin Lung Cancer. 2024 Dec;25(8):e393-e396. doi: 10.1016/j.cllc.2024.07.006. Epub 2024 Aug 1. Clin Lung Cancer. 2024. PMID: 39095236
Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study.
Hou X, Zhou C, Wu G, Lin W, Xie Z, Zhang H, Yi J, Peng Z, Yin L, Ma C, Chen L. Hou X, et al. Among authors: xie z. J Thorac Oncol. 2023 Jun;18(6):769-779. doi: 10.1016/j.jtho.2023.01.083. Epub 2023 Feb 2. J Thorac Oncol. 2023. PMID: 36738928 Free article. Clinical Trial.
Combined small cell lung cancer: current progress and unmet needs.
Zeng C, Qiu G, Xie X, Liu T, Chen Z, Zhang X, Zhou W, Lin X, Xie Z, Qin Y, Wang Y, Ma X, Zhou C, Liu M. Zeng C, et al. Among authors: xie x, xie z. Am J Cancer Res. 2023 Sep 15;13(9):3864-3874. eCollection 2023. Am J Cancer Res. 2023. PMID: 37818075 Free PMC article. Review.
12,530 results
You have reached the last available page of results. Please see the User Guide for more information.